Olema Pharmaceuticals Inc.
Organization details
- Legal name
- Olema Pharmaceuticals Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OLMA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001750284
- EIN
- 30-0409740
Board of directors
-
Andrew Rappaport · DirectorSince 2023
-
Cynthia M. Butitta · DirectorSince 2023
-
Cyrus Harmon · Director · Chief Research OfficerSince 2023
-
G. Walmsley Graham · DirectorSince 2023
-
Gorjan Hrustanovic · DirectorSince 2023
- Since 2023
-
J. Scott Garland · DirectorSince 2023
-
Mark N. Lampert · DirectorSince 2023
-
Prakash Raman · DirectorSince 2026
-
Sandra Horning · DirectorSince 2023
-
Sean Bohen · Director · PRESIDENT AND CEOSince 2023
-
Yi Larson · DirectorSince 2023
Chief executives
Director election results
Annual meeting of June 17, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
73.4%
-
98.0%
-
98.3%
Board connections
7 of this board's directors also sit on 20 other boards. 19 are in the same sector.
-
Kymera Therapeutics Inc. Same sectorvia Gorjan Hrustanovic and Mark N. Lampert
-
ALX Oncology Holdings Inc. Same sectorvia J. Scott Garland
- via Cynthia M. Butitta
-
BioMarin Pharmaceutical Inc. Same sectorvia Ian T. Clark
-
Black Diamond Therapeutics Inc. Same sectorvia Prakash Raman
-
Century Therapeutics Inc. Same sectorvia Cynthia M. Butitta
-
Corvus Pharmaceuticals Inc. Same sectorvia Ian T. Clark
-
Enliven Therapeutics Inc. Same sectorvia J. Scott Garland
-
Gilead Sciences Inc. Same sectorvia Sandra Horning
- via Ian T. Clark
-
Guardant Health Inc. Same sectorvia Ian T. Clark
-
Immunic Inc. Same sectorvia Mark N. Lampert
-
Kyverna Therapeutics Inc. Same sectorvia Ian T. Clark
-
LB Pharmaceuticals Inc Same sectorvia J. Scott Garland
-
Moderna Inc. Same sectorvia Sandra Horning
-
MoonLake Immunotherapeutics Same sectorvia Mark N. Lampert
-
Revolution Medicines Inc. Same sectorvia Sandra Horning
-
Takeda Pharmaceutical Company Limited Same sectorvia Ian T. Clark
-
Tectonic Therapeutic Inc. Same sectorvia Ian T. Clark
-
UroGen Pharma Ltd. Same sectorvia Cynthia M. Butitta
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $24,739,306
- 25 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 24, 2026 | Cyrus Harmon Director | Open-market sale | −12,500 | $11.71 | $146,375 |
| Jul 23, 2026 | Cyrus Harmon Director | Open-market sale | −12,500 | $11.58 | $144,750 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Option exercise | +25,000 | $4.37 | $109,250 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −24,767 | $24.25 | $600,600 |
| Mar 4, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −233 | $24.69 | $5,753 |
| Mar 3, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Option exercise | +15,000 | $4.37 | $65,550 |
| Mar 3, 2026 | Mitchell Shawnte Officer (CHIEF LEGAL OFFICER) | Open-market sale | −15,000 | $23.01 | $345,150 |
| Feb 2, 2026 | Austin Sasha Lu Officer (VP of Finance and Controller) | Grant or award | +11,700 | — | — |
| Jan 20, 2026 | Cyrus Harmon Director | Open-market sale | −10,000 | $26.88 | $268,800 |
| Jan 15, 2026 | Kovacs Shane William Charles Officer (CH. OPERATING & FINANCIAL OFF.) | Open-market sale | −100,000 | $28.73 | $2,873,000 |
| Jan 14, 2026 | Cyrus Harmon Director | Open-market sale | −3,489 | $29.12 | $101,600 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Option exercise | +50,000 | $4.87 | $243,500 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Open-market sale | −14,997 | $28.60 | $428,914 |
| Jan 14, 2026 | Myles David C. Officer (CH. DISCOV. & NON-CLIN DEV OFF) | Open-market sale | −35,003 | $28.99 | $1,014,737 |
| Jan 13, 2026 | Kovacs Shane William Charles Officer (CH. OPERATING & FINANCIAL OFF.) | Open-market sale | −3,822 | $28.01 | $107,054 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Olema Pharmaceuticals Inc.
Who is the CEO of Olema Pharmaceuticals Inc.?
Sean Bohen is Olema Pharmaceuticals Inc.'s President and CEO.
How many directors are on Olema Pharmaceuticals Inc.'s board?
Olema Pharmaceuticals Inc.'s board has 12 directors: Andrew Rappaport, Cynthia M. Butitta, Cyrus Harmon, G. Walmsley Graham, Gorjan Hrustanovic, Ian T. Clark, J. Scott Garland, Mark N. Lampert, Prakash Raman, Sandra Horning and 2 others.
Are Olema Pharmaceuticals Inc. insiders buying or selling shares?
Over the last 12 months, Olema Pharmaceuticals Inc. insiders made no open-market purchases and sold $24.7 million of shares in 25 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="olema-pharmaceuticals-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.